Active substance
Results for the substance gemtuzumab ozogamicin
1 result
About this active substance
Gemtuzumab ozogamicin is a medication used for the treatment of acute myeloid leukemia (AML) in adults. It is a monoclonal antibody conjugated with a chemotherapy agent that targets cancer cells expressing the CD33 protein.
This medication works by binding to cancer cells and delivering the chemotherapy agent directly into them, destroying the cells. It is administered intravenously under strict medical supervision.
Gemtuzumab ozogamicin may cause side effects, including fever, nausea, fatigue, low blood cell counts, or liver function impairment. In rare cases, veno-occlusive disease may occur.
It is essential to follow your doctor's instructions and undergo regular tests to monitor the treatment's effects and manage potential side effects.
This medication works by binding to cancer cells and delivering the chemotherapy agent directly into them, destroying the cells. It is administered intravenously under strict medical supervision.
Gemtuzumab ozogamicin may cause side effects, including fever, nausea, fatigue, low blood cell counts, or liver function impairment. In rare cases, veno-occlusive disease may occur.
It is essential to follow your doctor's instructions and undergo regular tests to monitor the treatment's effects and manage potential side effects.